glp-1 in type 1 diabetes patients with residual ß-cell function, treatment GLP-1 Receptor Agonists: A Game-Changer

Change from two doses of premix to a basal/bolus regimen with glargine, detemir or degludec The previous total dose of the NPH fraction of the mixture, which will be administered as a slow-acting analogue, should be reduced by 2030%

GLP-1 is studied because it connects nutrient sensing, endocrine signaling, and systemic metabolic regulation through activation of the GLP-1 receptor (GLP-1R)

K.HesseE.GazeW.KlmperU

While more research is needed, the data hint at a potential protective effect on joint tissues themselves

These findings showed that although the duration of treatment could explain some of the heterogeneity, it did not help predict the SMD between arms of studies

The coordinator and P.A